ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

molnupiravir

Also written as “Molnupiravir”, “EIDD-2801” and “MK-4482”.

Its studies are mostly in COVID-19 · Renal Insufficiency · Coronavirus Infections, led by 4 companies.

Drug pageMolnupiravir: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 30, 202014 company-led studies, 1 open or runningNext primary completion: Jan 26, 2031 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only91 open or runningphase 3since Sep 30, 2020Sep 30, 2020Jan 26, 2031phase 3 · NCT06667700
Ridgeback Biotherapeutics, LP30 open or runningphase 2since May 26, 2020Apr 29, 2020none ahead
Geropharmits history only10 open or runningno phasesince Dec 7, 2022Dec 7, 2022none ahead
Valenta Pharm JSCits history only10 open or runningno phasesince Jun 6, 2022Jun 6, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ridgeback Biotherapeutics, LP only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Apr 29, 2020First study: phase 1 study in Coronavirus InfectionsFirst studyNCT04392219 · 130 enrolled · United Kingdom
  2. May 26, 20202 phase 2 studiesNCT04405739, NCT04405570
  3. Dec 19, 2020Named molnupiravirINNProposed as its International Nonproprietary Name in WHO's List 124 · before, EIDD-2801, MK-4482

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“RNA disrupting agent”ChEMBL 37, by rule

Studies

All 3 Ridgeback Biotherapeutics, LP leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04405739SARS-CoV 2 · United States2CompletedFeb 21, 202271
NCT04405570COVID-19 · United States2CompletedFeb 21, 2021204
NCT04392219Coronavirus Infections · United Kingdom1CompletedAug 11, 2020130

How it is read

Names in the registry

  • “Molnupiravir”, 9 entries
  • “EIDD-2801”, 2 entries
  • “MK-4482”, 1 entry
  • “GP30341 capsules 200 mg”, 1 entry
  • “Molnupiravir 200 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.